Why the study?
Cognitive dysfunction is a core component affecting an estimated two-thirds of patients with MDD, motivating an assessment of how mood and cognitive symptoms change during treatment.
Does pharmacological antidepressant treatment improve cognitive dysfunction in patients with Major Depressive Disorder compared to healthy controls?
Does pharmacological antidepressant treatment improve cognitive dysfunction in patients with Major Depressive Disorder compared to healthy controls?
While standard antidepressant treatment effectively reduces mood symptoms in Major Depressive Disorder, cognitive deficits persist, highlighting the need for targeted cognitive therapies.
Supports tracking cognitive symptoms alongside mood in MDD; leaves open causal links from observational design.
Objective: Cognitive dysfunction is one of the core components of major depressive disorder (MDD). It is estimated that two-thirds of patients diagnosed with MDD have cognitive deficits. Cognitive symptoms are pervasive and affect functioning in several domains. This 16-week prospective case-control study aimed to assess the change of mood and cognitive symptoms during treatment. Materials and Methods: weeks). For mood symptoms, the Montgomery-Asberg Depression Rating Scale was used, and for neurocognitive functions, the Perceived Deficits Questionnaire-Depression was used, and the Digit Symbol Substitution Test was administered to both groups. Results: week. Conclusion: Our longitudinal research revealed that even though mood symptoms decreased and patients with depression did achieve symptomatic remission, their cognitive deficits perpetuated.
No takes yet. Share an insight, caveat, or question.
Çökmüş et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: